Ruben Escuro, MD
Hematology & Oncology · Elyria, OHNPI 1194777292
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $697 of the $882 with a category attached, or 79.0%. It is spread thinly across 26 manufacturers, the largest accounting for just 12.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $508 and has fallen 96.5% since, to $18 in 2024. That places this record below the midpoint for hematology & oncology clinicians in OH, where the typical reported total is $2,354.
Across 45 payments — averaging $19.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$113
- Pharmacyclics LLC, An Abbvie Company$72
- ASD Specialty Healthcare, LLC$61
- Novartis$59
- Bayer$57
- Eisai Inc.$49
- plus $471 from 20 others
What the payments were for
- Food & beverage$69779%
- Education$18521%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 7 | $113 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $72 |
| ASD Specialty Healthcare, LLC | 1 | $61 |
| Novartis | 4 | $59 |
| Bayer | 3 | $57 |
| Eisai Inc. | 3 | $49 |
| AstraZeneca | 2 | $47 |
| Astellas Pharma US Inc | 2 | $44 |
| Pfizer | 3 | $40 |
| Johnson & Johnson(2 entities) | 2 | $38 |
| Regeneron Healthcare Solutions, Inc. | 1 | $33 |
| Bristol Myers Squibb | 2 | $26 |
| Blueprint Medicines Corporation | 1 | $22 |
| Tesaro, Inc. | 1 | $21 |
| EMD Serono, Inc. | 1 | $20 |
| AbbVie | 1 | $20 |
| CSL Behring | 1 | $19 |
| Amgen | 1 | $19 |
| Genentech USA, Inc. | 1 | $18 |
| Sanofi | 1 | $18 |
| Secura Bio, Inc. | 1 | $18 |
| Seagen Inc. | 1 | $16 |
| Karyopharm Therapeutics Inc. | 1 | $15 |
| Merck | 1 | $14 |
| Lilly USA, LLC | 1 | $12 |
| Medtronic | 1 | $11 |
How this compares
$882 in reported general payments places this provider in the 35th percentile of 450 hematology & oncology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Elyria
- Hillard LazarusCleveland$2M
- Kasra KaramlouSandusky$1.8M
- David WaterhouseCincinnati$1.3M
- Taral PatelColumbus$888K
- Tarek ChidiacColumbus$765K
- Saulius GirniusMontgomery$707K
- Ronald BukowskiCleveland$594K
- Balazs HalmosCleveland$568K
- Jorge GarciaCleveland$513K
- Alejandro CalvoKettering$463K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.